Effectiveness of the probiotic B. bifidum 1 for the prevention of recurrent respiratory infections in children of 7–11 years old with functional and chronic disorders of gastrointestinal tract

Cover Page


Cite item

Abstract

Background: Acute respiratory infections (ARI) are a significant public health problem worldwide due to their high incidence and lack of specific prevention for most of them. Previous systematic reviews have demonstrated the possibility to use probiotics to prevent ARI in children. The prophylactic efficacy of the B. bifidum 1 strain in patients with recurrent ARI has not been investigated specifically against the background of concomitant gastrointestinal disorders, which may affect the effectiveness of probiotic therapy.

Aim: To evaluate the effectiveness and safety of the sorbed probiotic B. bifidum 1 for prevention of ARI in children of 7 to 11 years of age with functional intestinal disorders or gastritis / gastroduodenitis.

Materials and methods: This prospective, randomized, open-label study was completed by 44 children divided into two parallel groups: with and without administration of the sorbed B. bifidum 1 at 5 × 107 CFU three times daily for 21 days as a component of a comprehensive sanatorium treatment for recurrent ARI. The children were followed up for three months after the end of the treatment in a winter season, with assessment of frequency, severity and duration of ARI episodes.

Results: The use of B. bifidum 1 in children of 7–11 years old with functional and chronic gastrointestinal disorders reduced the incidence of upper respiratory tract infections (relative risk reduction 0.48, 95% confidence interval 0.15–0.68) and mean duration of respiratory diseases by 2.26 days (95% confidence interval 0.23–4.27). It also reduced fever, frequency of cases with cough and the need in antibiotic therapy. The efficacy was related mainly to a decrease in the number of children with more than one ARI episode during the three months of the winter season.

Conclusion: The results of probiotics use should be evaluated with consideration of underlying disease, which can more clearly indicate the size of their effect. The use of probiotics for prevention of infectious diseases, including respiratory infections, in children with functional and chronic gastrointestinal disorders can be promising in reduction of the overall morbidity and requires further studies.

About the authors

E. R. Meskina

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: meskinaelena@rambler.ru

Elena R. Meskina – MD, PhD, Head of Сhildren's Infectious Disease Department

61/2 Shchepkina ul., Moscow, 129110, tel.: +7 (916) 121 61 72

Russian Federation

E. A. Medvedeva

Moscow Regional Research and Clinical Institute (MONIKI)

Email: evgeniya0103med@yandex.ru

Evgeniya A. Medvedeva – MD, PhD, Junior Research Fellow, Сhildren's Infectious Disease Department.

61/2 Shchepkina ul., Moscow, 129110, tel.: +7 (926) 264 93 30

Russian Federation

L. V. Feklisova

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

Lyudmila V. Feklisova – MD, PhD, Professor, Chair of Pediatrics with Course of Children's Infections Disease, Postgraduate Training Faculty.

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

References

  1. Wishaupt JO, van der Ploeg T, de Groot R, Versteegh FG, Hartwig NG. Single- and multiple viral respiratory infections in children: disease and management cannot be related to a specific pathogen. BMC Infect Dis. 2017;17(1): 62. doi: 10.1186/s12879-016-2118-6.
  2. Toivonen L, Karppinen S, Schuez-Havupalo L, Teros-Jaakkola T, Vuononvirta J, Mertsola J, He Q, Waris M, Peltola V. Burden of recurrent respiratory tract infections in children: a prospective cohort study. Pediatr Infect Dis J. 2016;35(12):e362–9. doi: 10.1097/INF.0000000000001304.
  3. GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11): 1133–61. doi: 10.1016/S1473-3099(17)30396-1.
  4. Нурматов ЗШ. Оценка расходов, связанных с амбулаторным и стационарным лечением ОРВИ и гриппа и их осложнений. Эпидемиология и вакцинопрофилактика. 2015;14(5): 26–30.
  5. Santibanez P, Gooch K, Vo P, Lorimer M, Sandino Y. Acute care utilization due to hospitalizations for pediatric lower respiratory tract infections in British Columbia, Canada. BMC Health Serv Res. 2012;12:451. doi: 10.1186/14726963-12-451.
  6. Lara-Oliveros CA, De Graeve D, Franco F, Daza SP. Disease burden and medical cost-analysis of Acute Respiratory Infections in a low-income district of Bogotá. Rev Salud Publica (Bogota). 2016;18(4): 568–80. doi: 10.15446/rsap.v18n4.45485.
  7. Sarna M, Ware RS, Sloots TP, Nissen MD, Grimwood K, Lambert SB. The burden of community-managed acute respiratory infections in the first 2-years of life. Pediatr Pulmonol. 2016;51(12): 1336–46. doi: 10.1002/ppul.23480.
  8. McLean HQ, Peterson SH, King JP, Meece JK, Belongia EA. School absenteeism among schoolaged children with medically attended acute viral respiratory illness during three influenza seasons, 2012–2013 through 2014–2015. Influenza Other Respir Viruses. 2017;11(3): 220–9. doi: 10.1111/irv.12440.
  9. Schaad UB, Esposito S, Razi CH. Diagnosis and management of recurrent respiratory tract infections in children: a practical guide. Arch Pediatr Infect Dis. 2016;4(1):e31039. doi: 10.5812/pedinfect.31039.
  10. de Martino M, Ballotti S. The child with recurrent respiratory infections: normal or not? Pediatr Allergy Immunol. 2007;18 Suppl 18:13–8. doi: 10.1111/j.1399-3038.2007.00625.x.
  11. Горелов АВ, Плоскирева АА, Бондарева АВ, Каннер ЕВ. Пробиотики в комплексной профилактике респираторных инфекций. Вопросы практической педиатрии. 2014;9(5): 77–83.
  12. Araujo GV, Oliveira Junior MH, Peixoto DM, Sarinho ES. Probiotics for the treatment of upper and lower respiratory-tract infections in children: systematic review based on randomized clinical trials. J Pediatr (Rio J). 2015;91(5): 413–27. doi: 10.1016/j.jped.2015.03.002.
  13. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;(2):CD006895. doi: 10.1002/14651858.CD006895.pub3.
  14. Wang Y, Li X, Ge T, Xiao Y, Liao Y, Cui Y, Zhang Y, Ho W, Yu G, Zhang T. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(31):e4509. doi: 10.1097/MD.0000000000004509.
  15. King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr. 2014;112(1): 41–54. doi: 10.1017/S0007114514000075.
  16. Esposito S, Rigante D, Principi N. Do children's upper respiratory tract infections benefit from probiotics? BMC Infect Dis. 2014;14:194. doi: 10.1186/1471-2334-14-194.
  17. Laursen RP, Larnkjær A, Ritz C, Hauger H, Michaelsen KF, Mølgaard C. Probiotics and child care absence due to infections: a randomized controlled trial. Pediatrics. 2017;140(2). pii: e20170735. doi: 10.1542/peds.2017-0735.
  18. Hojsak I, Močić Pavić A, Kos T, Dumančić J, Kolaček S. Bifidobacterium animalis subsp. lactis in prevention of common infections in healthy children attending day care centers – randomized, double blind, placebo-controlled study. Clin Nutr. 2016;35(3): 587–91. doi: 10.1016/j.clnu.2015.05.004.
  19. Guarino A, Canani RB. Probiotics in childhood diseases: from basic science to guidelines in 20 years of research and development. J Pediatr Gastroenterol Nutr. 2016;63 Suppl 1:S1–2. doi: 10.1097/MPG.0000000000001220.
  20. Hojsak I. Probiotics in children: what is the evidence? Pediatr Gastroenterol Hepatol Nutr. 2017;20(3): 139–46. doi: 10.5223/pghn.2017.20.3.139.
  21. Amaral MA, Guedes GHBF, Epifanio M, Wagner MB, Jones MH, Mattiello R. Network meta-analysis of probiotics to prevent respiratory infections in children and adolescents. Pediatr Pulmonol. 2017;52(6): 833–43. doi: 10.1002/ppul.23643.
  22. González-Rodríguez I, Ruiz L, Gueimonde M, Margolles A, Sánchez B. Factors involved in the colonization and survival of bifidobacteria in the gastrointestinal tract. FEMS Microbiol Lett. 2013;340(1): 1–10. doi: 10.1111/15746968.12056.
  23. Vecchione A, Celandroni F, Mazzantini D, Senesi S, Lupetti A, Ghelardi E. Compositional quality and potential gastrointestinal behavior of probiotic products commercialized in Italy. Front Med (Lausanne). 2018;5:59. doi: 10.3389/fmed.2018.00059.
  24. Piano MD, Carmagnola S, Ballarè M, Balzarini M, Montino F, Pagliarulo M, Anderloni A, Orsello M, Tari R, Sforza F, Mogna L, Mogna G. Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form. J Clin Gastroenterol. 2012;46 Suppl:S85–92. doi: 10.1097/MCG.0b013e3182672796.
  25. Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther. 2018;35(3): 289–310. doi: 10.1007/s12325-018-0673-5.
  26. Alarcón T, Llorca L, Perez-Perez G. Impact of the Microbiota and Gastric Disease Development by Helicobacter pylori. Curr Top Microbiol Immunol. 2017;400:253–75. doi: 10.1007/978-3319-50520-6_11.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2018 Meskina E.R., Medvedeva E.A., Feklisova L.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies